Jump to content

Olaparib + Zytiga for Metastatic Castrate-Resistant Prostate Cancer: PCRI video


Recommended Posts

Jim Marshall (not a doctor) said ...

In this video Prostate Cancer Research Institute Executive Director Mark Scholz talks about a clinical trial for men who are metastatic and have rising psa on hormone therapy.

The trial is testing whether adding the PARP inhibitor Lynparza (olaparib) to the super-hormone Zytiga (abiraterone) increases its effectiveness.


You can find out about the clinical trial at:


Details there include:

  • inclusion details (things you need to get into the trial);
  • exclusion details (what will keep you out of the trial); and
  • locations.

Australian locations include:

  • Box Hill, Australia, 3128
  • Darlinghurst, Australia, 2010
  • Greenslopes, Australia, 4120
  • Herston, Australia, 4029
  • Kingswood, Australia, 2747
  • Kurralta Park, Australia, 5037
  • St Albans, Australia, 3021
  • Waratah, Australia, 2298


As always, ask your doctor if you think this might be for you.

... end Jim




Link to comment
Share on other sites

What's the theory behind adding a PAR-I if a man is NOT BRCA+??? To me it sounds like throwing spaghetti at the wall to see what sticks.  Scholz throws very little if any light on why they are combining these two drugs.

Link to comment
Share on other sites


This topic is now archived and is closed to further replies.

  • Create New...